InvestorsHub Logo
Post# of 252431
Next 10
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

Re: Mufaso post# 247031

Wednesday, 05/17/2023 4:40:13 PM

Wednesday, May 17, 2023 4:40:13 PM

Post# of 252431
The columns in that NASH-failure table appear to be out of alignment. E.g., Ocaliva is an FXR agonist, and Emricasan is a pan-caspase inhibitor.

Your main point—that so many companies have tried and failed at NASH—is well taken.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.